Why Doctors Ignore Most Drug Safety Alerts, and the TSXV-listed Company Trying to Fix It (TSXV: SEGN)

WSW, NY, June 23rd, 2026, FinanceWire

Inside the "alert fatigue" problem in modern medicine, and a look at Seegnal (TSXV: SEGN)*, a Canadian listed microcap working to solve it. New Coverage Disseminated on Behalf of Seegnal Inc.

Ask a hospital physician about the safety warnings that pop up when they write a prescription, and many will admit a quiet truth: they override almost all of them. Research backs that up. Reviews of electronic prescribing systems have found that clinicians override anywhere from roughly half to nearly all of the medication alerts they receive, and for drug-drug interaction warnings specifically, override rates often sit around 90% or higher. The phenomenon has a name, "alert fatigue," and it is one of the stranger failures in modern medicine: the very systems built to catch dangerous prescriptions generate so much noise that the warnings get tuned out. The stakes are not abstract: the World Health Organization estimates that medication errors cost health systems about USD $42 billion a year. The agency separately reports that more than half of all patient harm, about 1 in 20 patients, is preventable, with roughly half of that avoidable harm related to medications. Seegnal Inc. (TSXV: SEGN.V), a health technology company with major deployments in Israel, has built its platform around solving exactly that problem.

A big reason so many alerts get overridden is that too many of them are not specific enough to be useful. Legacy decision-support tools, including those embedded in widely used hospital record systems, lean heavily on rule-based checks against standard drug-safety databases, often flagging whether two drugs are known to interact. They typically do not weigh the patient in front of the doctor, their kidney function, lab results, age, diagnoses, or full list of current medications. So the same warning fires for everyone, whether or not the combination is actually risky for that particular person. The result is a flood of generic pop-ups, most of them irrelevant, and a predictable human response: click past them.

Consider a patient with failing kidneys who is prescribed a routine dose of gabapentin, a common nerve-pain drug. The order looks unremarkable, and a conventional system raises no objection, yet damaged kidneys cannot clear the drug, so it can build to many times a safe level and bring on serious neurotoxicity. The prescription was right on paper and wrong for that person. That is the gap Seegnal was built to close. According to the company, its platform plugs into the record systems used by hospitals, long-term care facilities, and physician offices and screens each prescription in real time against that specific patient's data, their labs, renal function, age, diagnoses, and medication history, before the drug is dispensed. When something is genuinely risky, it surfaces a single, plain alert explaining why, along with safer alternatives. When nothing is wrong for that patient, it stays quiet. The company frames the goal as fewer, more relevant interventions rather than more warnings.

There is peer-reviewed evidence that the approach changes the math. In a study published in the journal Drug Safety in 2021, researchers at Brigham and Women's Hospital, a Harvard teaching hospital, ran Seegnal's platform against the drug-safety alerts built into Epic, a widely used hospital record system, over the same 3,801 patients. In the inpatient group, Seegnal produced 94% fewer alerts, 1,697 against Epic's 27,540. Its specificity, a measure of how well a system avoids false alarms, was 99% versus 0.3%, meaning the legacy system flagged almost everything while Seegnal flagged almost nothing that did not warrant attention. In that inpatient setting, Seegnal also identified every case the reviewers classified as a genuine risk. Of the adverse drug events that occurred during the study, the reviewers judged that most could potentially have been prevented by the patient-specific system.

See Also >>

Healthcare Triangle Announces Closing of $3.6M Private Placement (NASDAQ: HCTI)

Empower, a CareCloud Company, Helps Wound-Care Provider Reverse More Than $1 Million in Alleged Overpayments

Aclarion Partners with PRIA Healthcare to Advance Reimbursement and Commercial Adoption of Its AI-Powered Nociscan Platform (NASDAQ: ACON)

Beyond the controlled comparison, Seegnal points to long-running use in Israel. A multi-year deployment at Leumit Health Services, one of the country's health maintenance organizations, using predecessor technology that underlies today's platform, was associated with fewer hospitalizations among higher-risk patients. The company reports that, as of May 2026, its system is deployed across Israeli hospitals and HMOs, screening more than 400,000 prescriptions a day for roughly 15,000 clinicians and 3.5 million patients, with more than 174 million prescriptions analyzed to date. Named users include Maccabi Healthcare Services, whose contract the company says runs through 2031, along with Tel Aviv Sourasky Medical Center and Rambam. These operating figures are company-reported and have not been independently audited.

The opportunity Seegnal is chasing is sizable. Third-party research from Grand View Research puts the global clinical decision support market at about $6.36 billion in 2025 and on track to reach roughly $15.32 billion by 2033, an 11.8% compound annual growth rate. The company has begun moving beyond Israel, announcing in May 2026 a letter of intent for its first pilot with a U.S.-based long-term care provider, a setting where elderly patients on many medications face some of the highest risk of preventable drug harm.

For investors, the picture is a clinically studied platform that is deployed at national scale in one country but still early in its commercial expansion elsewhere. Seegnal trades on the TSX Venture Exchange, its commercial activity, by the company's own reporting, remains concentrated in Israel, and turning a respected clinical record into international sales is a different challenge from building the technology itself. What is not in question is the underlying problem. As long as safety alerts remain easy to ignore, the case for systems that clinicians actually trust looks likely to keep growing.

Recent News Highlights from Seegnal (TSXV: SEGN.V):

Seegnal Successfully Initiates First U.S. Pilot Program

Seegnal Accepted into Innovative Accelerator Program from AARP, the Largest U.S. Organization Serving Americans 50 and Older

Seegnal Inc. Receives Gold Mark from the Standards Institution of Israel, Advancing Commercialization Readiness

* IMPORTANT NOTICE AND DISCLAIMER: This article is sponsored content released on behalf of Seegnal Inc. (“Seegnal”) and has been prepared, authored, and disseminated by Wall Street Wire. It is paid promotional content authored by the Wall Street Wire editorial team, not independent research, analysis, or journalism. As sponsored content, it carries inherent bias and potential conflicts of interest. Seegnal’s role was limited to review for factual accuracy of statements about the company. This article is not an official communication of Seegnal. The article is for informational purposes only and does not constitute investment advice, an offer to sell, or a solicitation of an offer to buy any securities. Wall Street Wire is compensated for this content on a cash-based subscription arrangement; engagement details are available at https://wallstwire.ai/disclosures. The information in this article is based on publicly available sources, including Seegnal’s prior press releases and filings, and has not been independently verified. Statements may constitute forward-looking information within the meaning of applicable securities laws; such statements involve risks and uncertainties, and actual results may differ materially. References to private companies, transactions, financial measures, or comparable data are drawn from publicly reported sources cited herein and are provided for thematic context only; they do not imply commercial relationships, endorsements, or comparable financial profiles with respect to Seegnal. Readers are encouraged to review Seegnal’s public filings on SEDAR+ (www.sedarplus.ca) for full details, including risk factors and any reconciliations of non-GAAP financial measures referenced. Investing in securities involves risk, particularly in venture-stage and microcap issuers; readers should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions. For full disclosure information, please visit https://wallstwire.ai/disclosures. Images are illustrative and generated by AI for conceptual purposes only. They do not depict Seegnal’s actual product, software, or user interface.

Contact